Boothbay Fund Management’s Aldeyra Therapeutics ALDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-16,521
Closed -$164K 1764
2023
Q1
$164K Buy
16,521
+2,996
+22% +$21.2K ﹤0.01% 1801
2022
Q4
$94.1K Buy
+13,525
New +$77.3K ﹤0.01% 1803
2022
Q3
Sell
-56,082
Closed -$224K 2209
2022
Q2
$224K Buy
56,082
+2,870
+5% +$9.87K 0.01% 1664
2022
Q1
$237K Buy
+53,212
New +$212K 0.01% 1783
2021
Q1
Sell
-18,277
Closed -$125K 1506
2020
Q4
$125K Buy
+18,277
New +$128K ﹤0.01% 1163
2020
Q3
Sell
-12,075
Closed -$50K 1021
2020
Q2
$50K Buy
12,075
+575
+5% +$2.1K ﹤0.01% 913
2020
Q1
$28K Buy
+11,500
New +$51.7K ﹤0.01% 804
2019
Q2
Sell
-136,800
Closed -$1.24M 719
2019
Q1
$1.24M Buy
136,800
+116,848
+586% +$993K 0.12% 192
2018
Q4
$166K Buy
+19,952
New +$204K 0.02% 508

Other funds holding ALDX

Boothbay Fund Management's ALDX Position: Q2 2023 in Review

Boothbay Fund Management sold out of Aldeyra Therapeutics (ALDX) in Q2 2023, closing a stake of 16,521 shares — an estimated $164K sold.

Boothbay Fund Management first reported a position in ALDX in Q4 2018 and held it in 9 quarters. The position peaked at $1.24M in Q1 2019. 119 funds tracked by Wall St. Rank hold ALDX as of Q2 2023.

  • Boothbay Fund Management reported no remaining Aldeyra Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 16,521 Aldeyra Therapeutics shares in Q2 2023, an estimated $164K.
  • Boothbay Fund Management first reported a position in Aldeyra Therapeutics in Q4 2018 and held it in 9 quarters.
  • Boothbay Fund Management's Aldeyra Therapeutics position peaked at $1.24M in Q1 2019.
  • 119 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2023.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.